AEON Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for AEON Biopharma (AEON).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$3Upside to Avg. PT+2017.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Lake Street	Thomas Flaten	PT Raise	Buy	$1→$2
Aug 14, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$5→$1
Jul 30, 2026	Lake Street	Thomas Flaten	Initiate	Buy	$1
Oct 8, 2025	Aegis Capital	David Bouchey	Maintained	Buy	$7
Oct 1, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$360
Aug 14, 2024	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$432→$360
Jul 10, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$432
May 30, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$432
May 15, 2024	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$1296→$432
May 6, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$1296
Apr 17, 2024	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$1296

Analyst Ratings News

Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday

Analysts raised targets for HPE, Phillips 66, Micron and AEON; cut targets for Liquidia, Apple and Zions.

Avi Kapoor

PRO
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2

Lake Street analyst Thomas Flaten maintains AEON Biopharma (AMEX:AEON) with a Buy and raises the price target from $1 to $2.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $5 to $1.2.

Benzinga Newsdesk

PRO
Aegis Capital Reiterates Buy on AEON Biopharma, Maintains $7.2 Price Target

Aegis Capital analyst David Bouchey reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $7.2 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $5

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $6 to $5.

Benzinga Newsdesk

AEON Biopharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

AEON Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday

PRO
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2

PRO
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2

PRO
Aegis Capital Reiterates Buy on AEON Biopharma, Maintains $7.2 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target

PRO
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $5

People Also Watch

People Also Watch

AEON Biopharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

AEON Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday

PROLake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2

PROHC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2

PROAegis Capital Reiterates Buy on AEON Biopharma, Maintains $7.2 Price Target

PROHC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target

PROHC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $5

People Also Watch

People Also Watch

PRO
Lake Street Maintains Buy on AEON Biopharma, Raises Price Target to $2

PRO
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2

PRO
Aegis Capital Reiterates Buy on AEON Biopharma, Maintains $7.2 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target

PRO
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $5